At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 261 enrolled
Drug / intervention
letrozoledrug
Likely dose
letrozole 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Single-arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who Are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-myalgia
In Brief
A Phase 4 clinical trial evaluating letrozole for Breast Cancer. Completed, enrolled 261 participants across 48 sites.
Detailed Summary
This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedJun 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedJun 3, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.1 years ago
Interventions
letrozoledrug
2.5 mg daily by mouth for 6 months